Comparison of EGFR mutation between supernatant and pellets of malignant pleural effusion from patients with advanced nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2018.01.003

Abstract

Abstract: ObjectiveTo compare the epidermal growth factor receptor (EGFR) mutation differences between supernatant and pellets of malignant pleural effusion (MPE) in advanced nonsmall cell lung cancer (NSCLC) patients and provide the evidence for clinical accurate detection. MethodsA total of 386 consecutive MPE specimens were collected in the study (202 in experimental group and 184 in validation group). Specimens in experimental group were divided into 4 groups depending on tumors cell concentration in the samples: zero cell (n=77), (15)×104/ml cells (n=43), (610)×104/ml cells (n=52) and >10×104/ml cells group (n=30). Amplification refractory mutation system (ARMS) was performed to detect EGFR gene mutation in supernatant and pellets of each individual case respectively, and the EGFR mutation positive rates were compared between the two groups. EGFR mutation test was carried out using either supernatant or pellets in validation group to verify the established method. ResultsIn the experimental group, the total EGFR mutation positive rate was 30.7% (62/202). In the zero cell group, EGFR mutation positive rate was higher in supernatant than that in pellets (37.6% vs. 33.8%). In the (15)×104/ml cells group and (610)×104/ml cells group, EGFR mutation positive rate was equal but not concordant between supernatant and pellets (25.6% and 21.1% respectively). In the >10×104/ml cells group, EGFR mutation positive rate was equal (33.3%) with 100% concordance between supernatant and pellets. In the validation group (n=184), EGFR mutation rate was 32.7% (36/110) in supernatant and 32.4% (24/74) in pellets, and there was no statistical significance (χ2=0.02, P=0.97). ConclusionTumor cell free MPE specimens from patients with advanced NSCLC are suitable for EGFR mutation test. Heterogeneity of MPE results in difference with respect to EGFR gene mutation status between cellfree supernatant and pellet. Pathological evaluation based on the quantity and quality of tumor cells in MPE patients prior to test and optional samples selection are necessary to increase EGFR mutation positive rate.

Key words: Pleural effusion, malignant, Receptor, epidermal growth factor, Mutation

Li Hui*, Yan Shi, Liu Yan, Liu Ying, Ma Lixia, Liu Xianhong, Cheng Ying. Comparison of EGFR mutation between supernatant and pellets of malignant pleural effusion from patients with advanced nonsmall cell lung cancer[J]. Journal of International Oncology, 2018, 45(1): 10-.

References

［1］ Sequist LV, Yang JC, Yamamoto NA, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations［J］. J Clin Oncol, 2013, 31(27): 33273334. DOI: 10.1200/JCO.2012.44.2806. ［2］ Jnne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitorresistant nonsmallcell lung cancer［J］. N Engl J Med, 2015, 372(18): 16891699. DOI: 10.1056/NEJMoa1411817. ［3］ Ma ES, Wong CL, Wong CL. EGFR gene mutation study in cytology specimens［J］. Acta Cytol, 2012, 56(6): 661668. DOI: 10.1159/000343606. ［4］ SaltoTellez M, Tsao MS, Shih JY, et al. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with nonsmall cell lung cancer: a combined clinicalmolecular pathological approach［J］. J Thorac Oncol, 2011, 6(10): 16631669. DOI: 10.1097/JTO.0b013e318227816a. ［5］ Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho［J］. Arch Pathol Lab Med, 2013, 137(6): 828860. DOI: 10.5858/arpa.20120720OA. ［6］ Wu SG, Hu FC, Chang YL, et al. Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis［J］. Eur Respir J, 2013, 41(2): 417424. DOI: 10.1183/09031936.00006912. ［7］ Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage nonsmallcell lung cancer (FASTACT2): a randomised, doubleblind trial［J］. Lancet Oncol, 2013, 14(8): 777786. DOI: 10.1016/S14702045(13)702547. ［8］ Hirsch FR, Jnne PA, Eberhardt WE, et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012［J］. J Thorac Oncol, 2013, 8(3): 373384. DOI: 10.1097/JTO.0b013e31827ed0ff. ［9］ Ebata T, Okuma Y, Nakahara Y, et al. Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis［J］. Thorac Cancer, 2016, 7(1): 3943. DOI: 10.1111/17597714.12271. ［10］ Liu D, Lu Y, Hu Z, et al. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma［J］. PLoS One, 2014, 9(2): e89946. DOI: 10.1371/journal.pone.0089946. ［11］ Lozano MD, Zulueta JJ, Echeveste JI, et al. Assessment of epidermal growth factor receptor and Kras mutation status in cytological stained smears of non small cell lung cancer patients: correlation with clinical outcomes［J］. Oncologist, 2011, 16(6): 877885. DOI: 10.1634/theoncologist.20100155. ［12］潘羡心, 孟加榕, 郭以河, 等. HRM方法检测肺腺癌患者癌性胸腔积液上清液EGFR基因突变的临床意义［J］. 现代肿瘤医学, 2014, 22(10): 23322335. DOI: 10.3969/j.issn.16724992.2014.10.22. ［13］ Lin J, Gu Y, Du R, et al. Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from nonsmall cell lung cancer patients by high resolution melting analysis and sequencing［J］. Int J Clin Exp Pathol, 2014, 7(12): 88138822. ［14］ Liu X, Lu Y, Zhu G, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced nonsmall cell lung cancer: comparison of methodologies［J］. J Clin Pathol, 2013, 66(12): 10651069. DOI: 10.1136/jclinpath2013201728. ［15］ Liu Y, Liu B, Li XY, et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of nonsmallcell lung cancer patients［J］. J Exp Clin Cancer Res, 2011, 30: 111. DOI: 10.1186/1756996630111. ［16］ Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced nonsmallcell lung cancer［J］. J Clin Oncol, 2011, 29(24): 33163321. DOI: 10.1200/JCO.2010.33.3757.

[1]	Li Bin, Zhang Guifang, Zhou Linjing, Yang Xiaodong, He Qiuli, Jia Sisi, Huang Puchao, Liang Jiaxin. Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer [J]. Journal of International Oncology, 2023, 50(5): 263-267.
[2]	Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang. Treatment status of non-small cell lung cancer with METexon14 skipping mutation [J]. Journal of International Oncology, 2023, 50(1): 37-41.
[3]	Zhou Ye, Yu Yan. MET14 exon skipping mutation and non-small cell lung cancer [J]. Journal of International Oncology, 2021, 48(6): 366-369.
[4]	Yi Zongbi, Ma Fei, Xu Binghe. Profile of gene mutations and targeted treatment of brain metastases in breast cancer [J]. Journal of International Oncology, 2019, 46(6): 354-357.
[5]	Wu Yuanyuan, Wang Jun. Advancement of targeted agents in the treatment of anaplastic thyroid carcinoma [J]. Journal of International Oncology, 2019, 46(2): 98-101.
[6]	Hu Wei, Zhang Yu. Analysis of gene detection status of EGFR mutation in 170 patients with advanced lung adenocarcinoma [J]. Journal of International Oncology, 2019, 46(1): 11-16.
[7]	Li Lixi, Ma Fei. Clinicopathological characteristics and susceptibility genes of early-onset breast cancer [J]. Journal of International Oncology, 2018, 45(4): 241-244.
[8]	Ma Yi, Xu Shun. Pulmonary adenocarcinoma shown as groundglass nodule: radiology, histopathology and molecular biology characteristics [J]. Journal of International Oncology, 2018, 45(10): 627-631.
[9]	DONG Rong-Rong, HE Xue-Xin, JI Jia-Li. Research process of APOBEC3B in breast cancer [J]. Journal of International Oncology, 2017, 44(8): 696-699.
[10]	CHAI Xiao-Yu, XU Meng, LIU Xin-Min. Research and application of NVPBEZ235 in lung cancer [J]. Journal of International Oncology, 2017, 44(5): 383-385.
[11]	SHAO Xi-Ying, ZHENG Ya-Bing, WANG Xiao-Jia. [J]. Journal of International Oncology, 2016, 43(8): 699-702.
[12]	Lin Li, Zhou Fuxiang. Relationship between mitochondrial DNA alteration and gastric cancer [J]. Journal of International Oncology, 2016, 43(8): 628-630.
[13]	Zhang Yu, Zhou Jianguo, Ma Hu. Molecular targeted therapy for non-small cell lung cancer and drug resistance [J]. Journal of International Oncology, 2016, 43(1): 45-48.
[14]	LIU Yan-Kui, WANG Xiao-Li, JIN Lin-Fang, QI Xiao-Wei. The value of peripheral blood circulating tumor cells in KRAS mutation testing of colorectal cancer patients [J]. Journal of International Oncology, 2015, 42(8): 653-.
[15]	Li Chen, Huang Yan. Advances of BRCA1, BRCA2 mutation and their clinical applications [J]. Journal of International Oncology, 2015, 42(2): 138-140.